Navigation Links
Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
Date:1/4/2008

orward-looking statements about the potential of the investigational compound prasugrel (CS-747, LY640315) and reflects Daiichi Sankyo's and Lilly's current beliefs. However, as with any pharmaceutical compound under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the compound will receive regulatory approval, that the regulatory approval will be for the indication(s) anticipated by the companies, or that later studies and patient experience will be consistent with study findings to date. There is also no guarantee that the compound will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filing with the United States Securities and Exchange Commission and Daiichi Sankyo's filings with the Tokyo Stock Exchange. Daiichi Sankyo and Lilly undertake no duty to update forward- looking statements.

Plavix(R)/Iscover(R) are registered trademarks of Sanofi-Synthelabo Inc. Effient(TM) is a trademark of Eli Lilly and Company.

P-LLY

(i) American Heart Association. Heart Disease and Stroke Statistics -

2006 Update. Dallas, TX. American Heart Association.

(ii) Bertrand CURE study

(iii) American Heart Association. Heart Attack and Angina Statistics.

URL: http://www.americanheart.org/presenter.jhtml?identifier=4591.

Last accessed July 26, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061120/DSLLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DAIICHI SANKYO EUROPE is Applying for Approval of its New Combination Product of Olmesartan and Amlodipin
2. Emisphere Technologies, Inc. and Eli Lilly and Company Settle Ongoing Litigation
3. Lilly Declares Fourth-Quarter Dividend
4. Robert Conley, M.D. to Join Lilly; Will assume a neuroscience leadership role as a Distinguished Lilly Scholar
5. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
6. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Adult stem cells that are required ... not magical. However, many current regenerative medicine ... if they were magical. , Many current clinical ... “stem cell tourism,” are evaluating heterologous tissue stem ... regenerative medicine therapies. In reality, these are not ...
(Date:7/22/2014)... LAKES, N.J. , July 22, 2014 The ... BDX ) has declared a quarterly dividend of ... to holders of record on September 9, 2014. The indicated ... About BD BD is a leading medical technology ... of the world,s most pressing and evolving health needs. Our ...
(Date:7/22/2014)... metal nanoparticles in water with ultrasound and they,ll spin ... No one yet knows exactly. But researchers at the ... their speedand it,s fast. At up to 150,000 revolutions ... any nanoscale object submerged in liquid ever reported. , ... the possibility that they could be used not only ...
(Date:7/22/2014)... Nuclear reactors are used to produce electricity ... chain reaction in nuclear reactors is used to create ... a power- generating turbine. Currently nuclear reactors are used ... production. Nuclear reactor market is expected to grow in ... nuclear reactor projects. , Early buyers will receive 10% ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Arpida Ltd,(SIX: ARPN) announced today its financial results for the year ending 31,December ... - Setback in regulatory process for intravenous iclaprim in US, ... - Top-line results of "intravenous-to-oral" Phase II trial with oral, ... change, - Share placing, Cash ...
... Feb. 25 Cerimon Pharmaceuticals, Inc., announced ... its once-daily topical diclofenac sodium patch Phase III program. ... Phase III clinical studies with Cerimon,s diclofenac patch. ... Cerimon,s diclofenac patch compared to placebo for the treatment ...
... SAN DIEGO and MONTREAL, Feb. 25 Speid ... consultancy firm today announced that it has entered ... success rates of new drug compounds using Genizon,s ... climate in which innovative pharmaceutical and biotechnology companies ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... of nanomaterials for application in devices may be addressed ... conducted by scientists from the National University of Singapore ... and low cost technique involving a focused laser beam, ... Haur from the Department of Physics at the NUS ... different types of materials can be controlled and modified, ...
(Date:7/22/2014)... milk helps make their bones strong or that fish is food ... if something is good for us, it must surely taste bad? ... Research , when children hear about the benefits of healthy food, ... food is presented to children as making them strong or as ... read or count, they would conclude the food is not as ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3
... 2010): Today, the Association for Molecular Pathology (AMP) submitted written ... the National Institutes of Health (NIH) for its Genetic Test ... to formulate a comprehensive response to the RFI. "With ... setting, AMP is able to inform the NIH on the ...
... While pundits write obituaries for the 2010 climate bill, ... the world. We are losing species and ecosystems are unraveling ... We need new tools and strategies to deal with these ... to announce the launch of their new Climate Adaptation Knowledge ...
... PHILADELPHIAIn 1824, three years before he began to publish his ... Audubon (1785-1851), the eminent artist of American birds and animals, ... the design for a New Jersey bank note. Although the ... in two separate diary entries, no one has ever been ...
Cached Biology News:AMP responds to Genetic Test Registry request for information 2CAKE offers way forward for climate change adaptation 2Discovered: Audubon's first engraving of a bird 2
...
... Forma Incubated Orbital Shakers combine high ... performance and ease of use. The ... allowing the unit to run at ... The unit's class-leading temperature range is ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
... have the durability to run ... and the uniformity and contamination ... applications. Heavily built with ... stackers are designed for ease ...
Biology Products: